Journal of hospital medicine : an official publication of the Society of Hospital Medicine
-
Postgraduate training for advanced practice providers (APPs) is a growing field in hospital medicine. As hospital programs continue to benefit from highly trained physician assistants (PAs) and nurse practitioners (NPs), fellowship programs have become more prevalent. However, little is known about the number of active programs or how they prepare trainees. ⋯ APP fellowships in hospital medicine are quickly growing as a means to train and retain nonphysician hospitalists. While most programs accept similar types of applicants and share a common rationale for program development, there is little standardization in terms of curriculum or assessment. Further research may be valuable to characterize the best practices to guide the future of these fellowships.
-
We compared prevalence estimates and prognostication if frailty were defined using the face-to-face Clinical Frailty Scale (CFS) or the administrative-data-derived Hospital Frailty Risk Score (HFRS). We evaluated 489 adults from a prospective cohort study of medical patients being discharged back to the community; 276 (56%) were deemed frail (214 [44%] on the HFRS and 161 [33%] on the CFS), but only 99 (20%) met both frailty definitions (kappa 0.24, 95% CI 0.16-0.33). Patients classified as frail on the CFS exhibited significantly higher 30-day readmission/death rates, 19% versus 10% for those not frail (aOR [adjusted odds ratio] 2.53, 95% CI 1.40-4.57) and 21% versus 6% for those aged >65 years (aOR 4.31, 95% CI 1.80-10.31). Patients with HFRS-defined frailty exhibited higher 30-day readmission/death rates that were not statistically significant (16% vs 11%, aOR 1.62 [95% CI 0.95-2.75] in all adults and 14% vs 11%, aOR 1.24 [95% CI 0.58-2.83] in those aged >65 years).
-
Among patients with nonvalvular atrial fibrillation (NVAF) who have sustained an upper gastrointestinal bleed (UGIB), the benefits and harms of oral anticoagulation change over time. Early resumption of anticoagulation increases recurrent bleeding, while delayed resumption exposes patients to a higher risk of ischemic stroke. We therefore set out to estimate the expected benefit of resuming anticoagulation as a function of time after UGIB among patients with NVAF. ⋯ For patients with NVAF following UGIB, warfarin is optimally restarted approximately six weeks following hemostasis, and apixaban is optimally restarted approximately one month following hemostasis. Modest changes to this timing based on probability of thromboembolic stroke are reasonable.